Standard BioTools (LAB) Stock Price
Standard BioTools Price
Revenue has compounded at 14.6% per year over the past 19 years to 85.33 M USD. Standard BioTools's net margin stands at -87.8%, down from -45.4% several years earlier. Analysts set a median price target of 1.58 USD, implying 159.2% above the current price. Of 7 analysts, 4 rate the stock a buy — an overall Buy consensus.
Standard BioTools stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Standard BioTools business model & stock analysis
Frequently asked questions about Standard BioTools
The business model of Fluidigm Corp focuses on providing innovative technologies for large-scale biological research. The company develops and sells microfluidic systems, instruments, consumables, and software solutions that enable scientists to analyze biological systems at the cellular level. Fluidigm Corp's platforms are designed to enhance workflows and deliver high-quality data for a wide range of applications, including genomics, proteomics, and single-cell analysis. By offering comprehensive and advanced solutions, Fluidigm Corp aims to empower researchers in their quest for new discoveries and deeper understanding of biological processes.
Fluidigm Corp is primarily active in the life sciences industry.
The main competitors of Fluidigm Corp in the market include companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies.
Fluidigm Corp is a renowned biotechnology company that specializes in the development and commercialization of innovative tools for life sciences research. Founded in 1999, Fluidigm Corp has consistently addressed critical challenges in various fields including genomics, proteomics, and single-cell analysis. The company's cutting-edge microfluidic technologies enable researchers to gain insights into biological systems with higher precision, efficiency, and cost-effectiveness. With a commitment to advancements in medical diagnostics, drug discovery, and personalized medicine, Fluidigm Corp continues to revolutionize the way researchers analyze and understand complex biological processes.
Fluidigm Corp has achieved significant milestones throughout its history. Some key accomplishments include the development and commercialization of innovative microfluidic solutions for life sciences research and clinical diagnostics. The company's revolutionary biomarker detection technology, CyTOF®, has gained widespread recognition for its ability to provide high-resolution single-cell analysis. Additionally, Fluidigm Corp has expanded its product portfolio by introducing high-throughput genotyping and gene expression systems, empowering researchers to unlock valuable insights into complex biological processes. The company's dedication to scientific excellence and ongoing innovation has helped establish Fluidigm Corp as a pioneering force in the field of microfluidics and life sciences.
Fluidigm Corp is primarily present in countries and regions across the globe. With a strong international presence, the company operates in key markets such as North America, Europe, Asia Pacific, and Latin America. Fluidigm Corp's cutting-edge technologies and innovative solutions have gained recognition and adoption worldwide, allowing it to serve customers and partners in various industries and research fields. From its headquarters in South San Francisco, California, Fluidigm Corp has expanded its reach, establishing offices, collaborations, and customer relationships in numerous countries and regions, solidifying its position as a global leader in pioneering microfluidic technologies and scientific advancements.
Fluidigm Corp represents a set of values and corporate philosophy centered around innovation, collaboration, and scientific advancement. With a focus on developing and commercializing transformative technologies, Fluidigm Corp strives to empower researchers and clinicians to make groundbreaking discoveries. The company's dedication to precision and accuracy in their microfluidic systems is evident in their commitment to providing customers with high-quality tools for genomic research, single-cell analysis, and mass cytometry. With a customer-centric approach, Fluidigm Corp aims to drive advancements in the fields of life sciences and healthcare by enabling deeper insights and accelerating discoveries.
Analysts currently set an average price target of 1.58 USD for the Standard BioTools stock (median: 1.58 USD), implying +159.2 % versus the latest price. The consensus is based on 7 analyst ratings.
8 analysts currently rate the Standard BioTools stock: 0 recommend buying, 3 holding and 5 selling. For 2026, analysts expect Standard BioTools to generate revenue of 82.50 M USD and earnings per share of -0.10 USD.
Converted at the current exchange rate, the Standard BioTools share trades at 0.54 EUR (0.61 USD).
The Standard BioTools share (LAB) is listed on 5 stock exchanges, including: NASDAQ (FLDM), SIX (Zürich) (FLB.SW), Frankfurt (FLB.F), München (FLB.MU), Düsseldorf (FLB.DU).
Fluidigm is a biotechnology company that develops innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The company was founded in 1999 and is headquartered in San Francisco, California. Fluidigm offers products and solutions for the study of single cells and cellular processes. The technology platforms include single-cell genomics, single-cell proteomics, and microfluidic systems. These platforms allow researchers to analyze and investigate individual cells. Fluidigm has a wide range of products that can be grouped into three main categories: gene expression, genotyping, and proteomics. Gene expression products are specifically designed for the analysis of single cells, including the C1 system and Biomark HD technology. The Biomark HD system is Fluidigm's flagship product and is used by researchers worldwide for comprehensive analysis of gene expression profiles. Fluidigm's genotyping product line is primarily used in the pharmaceutical industry and includes assays and chips that enable scientists to study individual genes in the human body. The assays are delivered by the EP1 platform, which performs highly precise genotyping processes and saves resources and time. Fluidigm's proteomics platform allows researchers to analyze proteins and proteome chains in single cells. The company offers a wide range of products, including chips, assays, and kits that detect the identity and concentration of proteins based on mass spectrometry. Fluidigm distributes its products worldwide and serves a broad customer base, including leading pharmaceutical and biotech companies, academic institutions, government agencies, and research laboratories. Fluidigm's business model is based on two core strategies, namely technology innovation and market penetration. The company continuously invests in research and development to remain at the forefront of its technology areas. This has resulted in a broad patent portfolio and a growing customer base. Fluidigm's market penetration strategy focuses on selling products to a variety of customers, including academic institutions, government agencies, and companies. The company has built a distribution infrastructure to sell its products worldwide and provide excellent customer support. In summary, Fluidigm is a biotechnology company that develops and sells innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The business model is based on technology innovation and market penetration strategy to sell its products worldwide and expand its customer base.
The expected revenue of Standard BioTools is 82.50 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Standard BioTools is -38.46 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Standard BioTools is currently -6.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Standard BioTools stock.
The price-to-sales ratio (P/S) of Standard BioTools is currently 2.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Standard BioTools stock.
The Eulerpool Quality Score for Standard BioTools is 3/10.
The ISIN of Standard BioTools is US34385P1084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Standard BioTools is A0RADJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Standard BioTools is LAB. The ticker symbol is used to trade Standard BioTools shares on the stock exchange.
Standard BioTools stock
Standard BioTools Peer Group
Standard BioTools Ticker
Standard BioTools FIGI
All fundamentals and in-depth analysis of Standard BioTools
Our stock analysis for Standard BioTools stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Standard BioTools. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.